Eagle Pharmaceuticals, Inc.

NASDAQ:EGRX

4.25 (USD) • At close September 6, 2024
Bedrijfsnaam Eagle Pharmaceuticals, Inc.
Symbool EGRX
Munteenheid USD
Prijs 4.25
Beurswaarde 55,194,750
Dividendpercentage 0%
52-weken bereik 3.21 - 17.32
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Scott L. Tarriff
Website https://www.eagleus.com

An error occurred while fetching data.

Over Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's

Vergelijkbare Aandelen

Coherus BioSciences, Inc. logo

Coherus BioSciences, Inc.

CHRS

1.24 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.5 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

2.4 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

11.3 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

2.62 USD

Quanterix Corporation logo

Quanterix Corporation

QTRX

11.99 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

19.12 USD

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

0.91 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)